Genomics

Dataset Information

0

NSCLC cells treated with Gefitinib


ABSTRACT: About 10% of all NSCLC patients respond to gefitnib treatment and all of these patients will acquire resistance to the EGFR TKI. We used microarray to look at global gene expression changes in untreated cells vs gefitinib treated cells to identify key characters for the acquisition of resistance.

ORGANISM(S): Homo sapiens

PROVIDER: GSE23206 | GEO | 2011/01/27

SECONDARY ACCESSION(S): PRJNA131643

REPOSITORIES: GEO

Similar Datasets

| E-GEOD-23206 | biostudies-arrayexpress
2016-07-01 | GSE75308 | GEO
2016-07-01 | GSE75307 | GEO
| E-GEOD-75307 | biostudies-arrayexpress
| E-GEOD-75308 | biostudies-arrayexpress
2017-06-02 | GSE95590 | GEO
2017-06-02 | GSE95558 | GEO
2018-02-21 | GSE110815 | GEO
| E-MTAB-9452 | biostudies-arrayexpress
2019-12-31 | GSE123066 | GEO